{ "ok": true, "cik": "1819411", "ticker": "GANX", "name": "GAIN THERAPEUTICS, INC", "filings": [ { "form": "8-K", "filed": "2026-09-28", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926111391/0001104659-26-111391-index.htm" }, { "form": "10-Q", "filed": "2026-08-11", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926094048/0001104659-26-094048-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/0001104659-26-094041-index.htm" }, { "form": "8-K", "filed": "2026-07-16", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/0001104659-26-084086-index.htm" }, { "form": "8-K", "filed": "2026-06-29", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926078848/0001104659-26-078848-index.htm" }, { "form": "8-K", "filed": "2026-06-25", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926077820/0001104659-26-077820-index.htm" } ], "events12m": 16, "healthWatch": { "window": "last 12 months", "since": "2025-09-29", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 2, "latest": { "filed": "2026-09-28", "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926111391/0001104659-26-111391-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001819411.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1819411" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up GAIN THERAPEUTICS, INC ($GANX). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-09-28. 16 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2023-12-31", "revenue": 55180, "revenueGrowth1y": -0.6061609615439518, "revenueGrowthPerYear": 0.2410444892845227, "yearsOfData": 4, "operatingMargin": -403.28258426966295, "operatingMarginPrior": -126.88101321837439, "netMargin": -403.54331279449076, "operatingCashFlow": -18865873, "capitalSpending": 15358, "freeCashFlow": -18881231, "researchAndDevelopment": 11520613, "researchShareOfRevenue": 208.78240304458137, "cash": 11794949, "longTermDebt": 567850, "longTermDebtChange": -0.05890522428997358, "revenueHistory": [ { "fiscalYearEnd": "2020-12-31", "revenue": 28881 }, { "fiscalYearEnd": "2021-12-31", "revenue": 164994 }, { "fiscalYearEnd": "2022-12-31", "revenue": 140108 }, { "fiscalYearEnd": "2023-12-31", "revenue": 55180 } ], "totalEquity": 12578224, "totalAssets": 18609331, "equityRatio": 0.6759095208742324, "returnOnEquity": -1.7703230599168849, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -1.71, "sharesOutstanding": 13011361, "bookValuePerShare": 0.9667108613772226, "revenuePerShare": 0.004240909156236615, "range80": { "low": 21300.829366487167, "high": 92465.6416451988, "baseline": 45101.3757592655, "n": 2483, "band": "b000", "bandLabel": "under $50M", "method": "v4.1", "credibility": 0.25, "growthYears": 2, "ownVolatility": 0.5432824642721257, "classVolatility": 0.3000583276631395, "volatility": 0.37591915220749045 }, "ifPaceHeld": { "low": 21300.829366487167, "high": 92465.6416451988 } }, "edgarette": "🔖 Exposure: revenue $55K (FY2023), total debt $568K. Experience: revenue down 60.6% on the year, up 24.1% a year over 3 years; operating margin -40328.3%, down from -12688.1%. Soundness: equity 67.6% of assets, return on equity -177.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $21K and $92K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $19K to $103K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -40328.3% against a -3.8% median; growth -60.6% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Gain Therapeutics, Inc (GANX) saw revenue fall 60.6% in FY2023 to $0 million, operating margin -40328% against a -3.8% median for pharmaceutical preparations, equity 67.6% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
GAIN THERAPEUTICS, INC against its own record and its peers
Operating marginPeer median -3.8%-40328.3%Revenue, on the yearPeer median 13.7%-60.6%Equity of assetsPeer median 40.3%67.6%Return on equityPeer median -1.1%-177.0%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v4", "byYear": {}, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Gain Therapeutics, Inc (GANX) saw revenue fall 60.6% in FY2023 to $0 million, operating margin -40328% against a -3.8% median for pharmaceutical preparations, equity 67.6% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2023-12-31", "revenue": 55180, "totalDebt": 567850, "cash": 11794949 }, "experience": { "revenueGrowth1y": -0.6061609615439518, "revenueGrowthPerYear": 0.2410444892845227, "operatingMargin": -403.28258426966295, "operatingMarginPrior": -126.88101321837439, "netMargin": -403.54331279449076, "freeCashFlow": -18881231 }, "soundness": { "equityRatio": 0.6759095208742324, "returnOnEquity": -1.7703230599168849, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 4, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-09-29", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 2, "latest": { "filed": "2026-09-28", "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926111391/0001104659-26-111391-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 21300.829366487167, "high": 92465.6416451988, "baseline": 45101.3757592655, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 2483, "sizeBand": "under $50M", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.25, "growthYears": 2, "ownVolatility": 0.5432824642721257, "classVolatility": 0.3000583276631395, "pricedVolatility": 0.37591915220749045, "k": 3 }, "stress": { "low": 19260.775109748756, "high": 102617.8299610658, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v4", "byYear": {}, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": null, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001819411.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1819411" }, "speedCash": null, "harbor": { "signs": [ { "key": "range", "text": "revenue is hard to predict: its 80% range is ±63%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2023-12-31", "operating": -18865873, "investing": 10222667, "financing": 12641343, "capitalSpending": 15358, "free": -18881231, "trend": [ { "fiscalYearEnd": "2020-12-31", "operating": -3240237, "free": -3261063 }, { "fiscalYearEnd": "2021-12-31", "operating": -12365670, "free": -12459882 }, { "fiscalYearEnd": "2022-12-31", "operating": -14692139, "free": -14811092 }, { "fiscalYearEnd": "2023-12-31", "operating": -18865873, "free": -18881231 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2023-12-31", "cash": 11794949, "shortTerm": 4999704, "longTerm": null, "equityHoldings": null, "totalAssets": 18609331, "ladder": null, "currentRatio": 3.59, "unrealizedGain": null, "unrealizedLoss": 4975, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": null, "harbor": { "signs": [ { "key": "range", "text": "revenue is hard to predict: its 80% range is ±63%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2023-12-31", "operating": -18865873, "investing": 10222667, "financing": 12641343, "capitalSpending": 15358, "free": -18881231, "trend": [ { "fiscalYearEnd": "2020-12-31", "operating": -3240237, "free": -3261063 }, { "fiscalYearEnd": "2021-12-31", "operating": -12365670, "free": -12459882 }, { "fiscalYearEnd": "2022-12-31", "operating": -14692139, "free": -14811092 }, { "fiscalYearEnd": "2023-12-31", "operating": -18865873, "free": -18881231 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2023-12-31", "cash": 11794949, "shortTerm": 4999704, "longTerm": null, "equityHoldings": null, "totalAssets": 18609331, "ladder": null, "currentRatio": 3.59, "unrealizedGain": null, "unrealizedLoss": 4975, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }